WO2003091384A3 - A role for survivin in apoptosis of myeloid cells - Google Patents

A role for survivin in apoptosis of myeloid cells Download PDF

Info

Publication number
WO2003091384A3
WO2003091384A3 PCT/GB2003/001753 GB0301753W WO03091384A3 WO 2003091384 A3 WO2003091384 A3 WO 2003091384A3 GB 0301753 W GB0301753 W GB 0301753W WO 03091384 A3 WO03091384 A3 WO 03091384A3
Authority
WO
WIPO (PCT)
Prior art keywords
apoptosis
survivin
iii
polypeptide
set out
Prior art date
Application number
PCT/GB2003/001753
Other languages
French (fr)
Other versions
WO2003091384A2 (en
Inventor
Ian Hayes
Tom Cotter
Liam Seery
Finbar Murphy
Frank Altznauer
Uwe Zangemeister-Wittke
Hans-Uwe Simon
Original Assignee
Eirx Therapeutics Ltd
Ian Hayes
Tom Cotter
Liam Seery
Finbar Murphy
Frank Altznauer
Uwe Zangemeister-Wittke
Hans-Uwe Simon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eirx Therapeutics Ltd, Ian Hayes, Tom Cotter, Liam Seery, Finbar Murphy, Frank Altznauer, Uwe Zangemeister-Wittke, Hans-Uwe Simon filed Critical Eirx Therapeutics Ltd
Priority to AU2003229930A priority Critical patent/AU2003229930A1/en
Publication of WO2003091384A2 publication Critical patent/WO2003091384A2/en
Publication of WO2003091384A3 publication Critical patent/WO2003091384A3/en
Priority to US10/972,576 priority patent/US20060160095A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a method for detecting apoptosis in a myeloid cell comprising detecting an alteration in any one of: i) a Survivin polypeptide having an amino acid sequence as set out in SEQ ID NO: 1; ii) a polypeptide having at least 80 % homology with i); iii) a nucleic acid encoding a polypeptide having the sequence set out in i) or ii); iv) a nucleic acid which hybridises under stringent conditions to the sequence set out in iii); or v) the complement of iii) or iv). The invention accordingly provides a method of modulating apoptosis in neutrophils by modulating Survivin gene expression and a method of treating inflammatory disease by modulating Survivin gene expression of function.
PCT/GB2003/001753 2002-04-24 2003-04-23 A role for survivin in apoptosis of myeloid cells WO2003091384A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003229930A AU2003229930A1 (en) 2002-04-24 2003-04-23 A role for survivin in apoptosis of myeloid cells
US10/972,576 US20060160095A1 (en) 2002-12-13 2004-10-25 Survivin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37519002P 2002-04-24 2002-04-24
US60/375,190 2002-04-24
US43312602P 2002-12-13 2002-12-13
US60/433,126 2002-12-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/972,576 Continuation US20060160095A1 (en) 2002-12-13 2004-10-25 Survivin

Publications (2)

Publication Number Publication Date
WO2003091384A2 WO2003091384A2 (en) 2003-11-06
WO2003091384A3 true WO2003091384A3 (en) 2004-02-12

Family

ID=29273021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/001753 WO2003091384A2 (en) 2002-04-24 2003-04-23 A role for survivin in apoptosis of myeloid cells

Country Status (2)

Country Link
AU (1) AU2003229930A1 (en)
WO (1) WO2003091384A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4503590B2 (en) * 2003-02-10 2010-07-14 サンタリス ファーマ アー／エス Oligomer compounds for regulating survivin expression
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
US20060154888A1 (en) 2004-11-09 2006-07-13 Santaris Pharma A/S LNA oligonucleotides and the treatment of cancer
DE602005023772D1 (en) * 2004-11-09 2010-11-04 Santaris Pharma As LNA OLIGONUCLEOTIDES AND CANCER TREATMENT
WO2008012563A2 (en) * 2006-07-28 2008-01-31 University Court Of The University Of Edinburgh Use of cdk inhibitors for the treatment of granulocyte mediated disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057059A1 (en) * 2000-02-02 2001-08-09 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057059A1 (en) * 2000-02-02 2001-08-09 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ADIDA COLETTE ET AL: "Expression and prognostic significance of survivin in de novo acute myeloid leukaemia", BRITISH JOURNAL OF HAEMATOLOGY, vol. 111, no. 1, October 2000 (2000-10-01), pages 196 - 203, XP002258069, ISSN: 0007-1048 *
AMBROSINI G ET AL: "A NOVEL ANTI-APOPTOSIS GENE, SURVIVIN, EXPRESSED IN CANCER AND LYMPHOMA", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 3, no. 8, August 1997 (1997-08-01), pages 917 - 921, XP002074968, ISSN: 1078-8956 *
CONWAY EDWARD M ET AL: "Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions.", BLOOD, vol. 95, no. 4, 15 February 2000 (2000-02-15), pages 1435 - 1442, XP002251969, ISSN: 0006-4971 *
FUKUDA SEIJI ET AL: "Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34+ cells by hematopoietic growth factors: Implication of survivin expression in normal hematopoiesis.", BLOOD, vol. 98, no. 7, 1 October 2001 (2001-10-01), pages 2091 - 2100, XP002251970, ISSN: 0006-4971 *
KABULI M ET AL: "Survivin-targeting DNAzymes suppress proliferation and induce apoptosis in myeloid leukaemic cells.", BRITISH JOURNAL OF HAEMATOLOGY, vol. 113, no. Supplement 1, May 2001 (2001-05-01), Annual Scientific Meeting of the British Society for Haematology;Harrogate, England, UK; April 23-26, 2001, pages 28, XP002251965, ISSN: 0007-1048 *
LI F ET AL: "Pleiotropic cell-division defects and apoptosis induced by interference with survivin function.", NATURE CELL BIOLOGY. ENGLAND DEC 1999, vol. 1, no. 8, December 1999 (1999-12-01), pages 461 - 466, XP001034788, ISSN: 1465-7392 *
LI FENGZHI ET AL: "Control of apoptosis and mitotic spindle checkpoint by survivin", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 396, no. 6711, 10 December 1998 (1998-12-10), pages 580 - 584, XP002183549, ISSN: 0028-0836 *
MAHOTKA CSABA ET AL: "Survivin-DELTAEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties.", CANCER RESEARCH, vol. 59, no. 24, 15 December 1999 (1999-12-15), pages 6097 - 6102, XP002251968, ISSN: 0008-5472 *
OLIE ROBERT A ET AL: "A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 11, 1 June 2000 (2000-06-01), pages 2805 - 2809, XP002210584, ISSN: 0008-5472 *
O'NEILL A J ET AL: "Inhibitors of apoptosis proteins expressed at a basal level in normal or inflammatory neutrophils", FASEB JOURNAL, vol. 15, no. 4, 7 March 2001 (2001-03-07), Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biol;Orlando, Florida, USA; March 31-April 04, 2001, pages A335, XP009018744, ISSN: 0892-6638 *
TAMM I ET AL: "IAP-FAMILY PROTEIN SURVIVIN INHIBITS CASPASE ACTIVITY AND APOPTOSISINDUCED BY FAS (CD95), BAX, CASPASES, AND ANTICANCER DRUGS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, no. 23, 1 December 1998 (1998-12-01), pages 5315 - 5320, XP001041463, ISSN: 0008-5472 *
TOBAL KHALID ET AL: "Expression and DNAzyme targeting of the apoptosis inhibitor, survivin in myeloid leukemias.", BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 216a, XP009019357, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2003091384A2 (en) 2003-11-06
AU2003229930A1 (en) 2003-11-10
AU2003229930A8 (en) 2003-11-10

Similar Documents

Publication Publication Date Title
NZ595500A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
ZA967173B (en) Purified coprinus laccases and nucleic acids and encoding same
SE9901298D0 (en) Xylose isomerase with improved kinetic properties
MX2011011215A (en) Carbohydrate degrading polypeptide and uses thereof.
EP1622921A4 (en) Variants of beta-glucosidases
WO2008070082A3 (en) Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
MY137803A (en) Production of tnfr-ig
BR9814404A (en) "expression cloning in filamentous fungi"
IL86480A0 (en) Recombinant dna coding for human proapolipoprotein a-i,expression vectors containing it and cells transformed by said expression vector
DK0698105T3 (en) Nucleotide sequences to control the expression of DNA sequences in a host cell
DE69634640D1 (en) MUTATED ALPHA-AMYLASE ENZYME WITH INCREASED STABILITY
SG158092A1 (en) Production of polypeptides
LV12814B (en) Cyclic gmp-binding, cyclic gmp-specific phosphodiesterase materials and methods
AU2003264419A1 (en) Kdr peptides and vaccines containing the same
ATE284954T1 (en) HYALURONAN SYNTHASE GENE AND ITS USE
HK1158529A1 (en) Promoters exhibiting endothelial cell specificity and methods of using same
DE69930955D1 (en) POLYPEPTIDES WITH LYSOPHOSPHOLIPASE ACTIVITY AND NUCLEIC ACIDS YOU CODE
ATE450603T1 (en) POLYPEPTIDES WITH BRANCHING ENZYME ACTIVITY AND NUCLEIC ACIDS ENCODING THEM
CA2327266A1 (en) Pesticidal toxins and nucleotide sequences which encode these toxins
WO2003091384A3 (en) A role for survivin in apoptosis of myeloid cells
AU6724794A (en) GRB3-3 gene, its variants and their uses
EP1728859A4 (en) Sequence capable of accelerating gene expression at moderately low temperature
WO2003048767A3 (en) Use of elavl-1 gene in the detection and modulation of apoptosis
WO2003048361A3 (en) P55pik
EP1195382A3 (en) Testis-specific gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10972576

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10972576

Country of ref document: US